Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations;CLSI ve EUCAST Önerilerine Göre Genişlemiş Spektrumlu Beta-Laktamaz Üreten Escherichia coli ̄drar ̄zolatlarinda Fosfomisin Duyarliliʇi

Mikrobiyoloji Bulteni

Volumn 48, Issue 4, 2014, Pages 545-555

  Aktaş, Sabahat Çaʇan ^a   Gençer, Serap ^a   Batirel, Ayşe ^a   Haciseyitoʇlu, Demet ^a   Özer, Serdar ^a  

^a DR LUTFI KIRDAR KARTAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Antimicrobial susceptibility; CLSI; ESBL; Escherichia coli; EUCAST; Fosfomycin

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; FOSFOMYCIN;

ADULT; DISK DIFFUSION; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI INFECTIONS; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; OUTPATIENT; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI;

ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DISK DIFFUSION ANTIMICROBIAL TESTS; ESCHERICHIA COLI INFECTIONS; FEMALE; FOSFOMYCIN; HUMANS; INPATIENTS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OUTPATIENTS; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI;

EID: 84916603097     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: 10.5578/mb.8327     Document Type: Article

References (31)

1. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum (beta)-lactamase producing Escherichia coir, changing epidemiology and clinical impact. Curr Opin Infect Dis 2010;23(4):320-6.
2. Goettsch W, van Pelt W, Nagelkerke N, et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the netherlands. J Antimicrob Chemother 2000;46(2):223-8.
3. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents 2003;22(Suppl 2):79-83.
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-first Informational Supplement. CLSI Document M100-S21, 2011. CLSI, Wayne, PA.
5. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, January 5, 2011. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test-documents/EUCAST-breakpoints-v1.3-pdf.pdf
6. Stürenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003;47(4):273-95.
7. Aykan SB, Ciftci IH. Antibiotic resistance patterns of Escherichia coli strains isolated from urine cultures in Turkey: a meta-analysis. Mikrobiyol Bul 2013;47(4):603-18.
8. Hosbul T, Ozyurt M, Baylan O, et al. In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections. Mikrobiyol Bul 2009;43(4):645-9.
9. Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis 2013;17(11):e966-70.
10. Öztürk CE, Kaya AD, Göçmen Ş, Arslan E. Toplum kaynakli idrar yolu infeksiyonu etkeni olani Escherichia coli izolatlarinin fosfomisin ile idrar yolu infeksiyonlarinda sik kullanilan antibiyotiklere duyarliliktan. ANKEM Derg 2008;22(2):81-4.
11. Mengeloʇlu FZ, Demircan F, Oduncu MK. ̄drar kültürlerinden soyutlanan Escherichia coli izolatlarinin fosfomisine karşi in-vitro duyarliliklarinin deʇerlendirilmesi. ANKEM 2011;25(2):99-102.
12. Pullukçu H, Aydemir SŞ, Taşbakan M, et al. Is there a rise in resistance rates to fosfomycin and other commonly used antibiotics in Escherichia coli-mediated urinary tract infections? A perspective for 2004-2011. Turk J Med Sci 2013;43(4):537-41.
13. Arman D, Aʇalar C, Dizbay M ve ark. Birinci basamak saʇlik merkezlerinde toplum kökenli alt üriner sistem enfeksiyonlan: etkenler ve antimikrobiyal duyarliliklari. Mediterr J Infect Microb Antimicrob 2012;1:10.
14. Uzun A, Gulen D, Tanriverdi Y, Kaya AD. Fosfomisin ve bazi antimikrobiyal ajanlarin üriner Escherichia coli ̄zolatlarina in vitro etkinliʇinin deʇerlendirilmesi. Klimik Derg 2012;25(2):77-80.
15. Tekin A, Deveci Ö, Dal T, Tekin R, Özekinci T, Dayan S. Üropatojen Escherichia coli izolatlanna fosfomisin ve bazi antibiyotiklerin in vitro etkinliʇi. ANKEM 2012;26(2):61-8
16. Oteo J, Bautista V, Lara N, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010;65(11):2459-63.
17. Östholm Balkhed A, Tarnberg M, Monstein HJ, Hallgren A, Hanberger H, Nilsson LE. High frequency of co-resistance in CTX-M-producing Escherichia coli to non-beta-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden. Scand J Infect Dis 2013;45(4):271-8.
18. Titelman E, Iversen A, Kahlmeter G, Giske CG. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS 2011;119(12):853-63.
19. Fournier D, Chirouze C, Leroy J, et al. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal Infect 2013;43(2):62-6.
20. Rodriguez-Avial C, Rodriguez-Avial I, Hernandez E, Picazo JJ. Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011). Rev Esp Quimioter 2013;26(1):43-6.
21. Gupta V, Rani H, Singla N, Kaistha N, Chander J. Determination of extended-spectrum beta-lactamases and AmpC production in uropathogenic isolates of Escherichia coli and susceptibility to fosfomycin. J Lab Physicians 2013;5(2):90-3.
22. Lee SY, Park YJ, Yu JK, et al. Prevalence of acquired fosfomycin resistance among extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J Antimicrob Chemother 2012;67(12):2843-7.
23. Habeeb MA, Sarwar Y, Ali A, Salman M, Haque A. Rapid emergence of ESBL producers in E.coli causing urinary and wound infections in Pakistan. Pak J Med Sci 2013;29(2):540-4.
24. Nakamura T, Komatsu M, Yamasaki K, et al. Susceptibility of various oral antibacterial agents against extended spectrum (3-lactamase producing Escherichia coli and Klebsiella pneumoniae. J Infect Chemother 2014;20(1):48-51.
25. Qiao LD, Chen S, Yang Y, et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013;3(12):e004152.
26. Araj GF, Jaber FA. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. J Med Liban 2012;60(3):142-7.
27. Hombach M, Mouttet B, Bloemberg GV. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC p-lactamase-producing clinical Enterobacteriaceae isolates. J Antimicrob Chemother 2013;68(9):2092-8.
28. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Hombach M. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum p-lactamase production in clinical Enterobacteriaceae isolates. J Antimicrob Chemother 2012;67(1):159-66.
29. Rodriguez-Bano J, Picon E, Navarro MD, Lopez-Cerero L, Pascual A; ESBL-REIPI Group. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum P-lactamase-producing Escherichia coli. Clin Microbiol Infect 2012;18(9):894-900.
30. Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010;65(9):1862-77.
31. Ferraro G, Ambrosi G, Bucci L, Palmieri R, Palmieri G. Fosfomycin trometamol versus norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly. Chemotherapy 1990;36(Suppl 1):46-9.